Veliflapon - Moligand™, 10 mM in DMSO , CAS No.128253-31-6

CAS: 128253-31-6 Cat. No.: V1496908 Formula: C₂₃H₂₃NO₃ Peso molecolare: 361.43 Numero EC: 802-979-7

QUALITÀ & PUREZZA Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein ( FLAP ) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.

Specifiche

Specifiche e purezza

Moligand™, 10 mM in DMSO

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Grado

Moligand™

Proprietà del prodotto

ALogP

5.4

Nomi e identificatori

Isomeri SMILES

C1CCC(C1)[C@H](C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O

Peso molecolare

361.43

Reaxy-Rn

13469407

Reaxys-RN_link_address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=13469407&ln=

Application Protocols

No tested application protocols are provided by the manufacturer for this item. The following are general guidelines for small-molecule screening in vitro:

• Stock preparation: Dissolve in anhydrous DMSO at 10–50 mM. Sonication or brief warming (≤40 °C) may assist dissolution. Aliquot to single-use volumes.
• Biochemical assays: Titrate over a broad concentration range (e.g., 0.1 nM–100 µM) using serial dilutions in DMSO. Maintain constant final DMSO across wells (typically 0.5–1.0% v/v). Include vehicle and positive controls.
• Cell-based assays: Verify cytotoxicity of vehicle; begin with ≤0.1–0.5% DMSO if possible. Pre-screen for precipitation in complete media. Consider time-course experiments to assess onset and reversibility.
• Biophysical binding: For SPR/ITC/DSF, ensure buffer-matched DMSO between sample and reference channels. Filter and degas solutions; verify absence of aggregates (DLS if available).

Record exact solvent percentages, plate type, and dispensing method in your ELN for reproducibility.

Biological Roles

Manufacturer-supplied biological target details are not provided for this item.

Context from open literature (for background only; verify independently for your application):

• Veliflapon has been described in the literature as a bioactive small molecule investigated in the arachidonic acid/leukotriene biosynthesis pathway, frequently discussed in relation to 5-lipoxygenase-activating protein (FLAP). Specific binding parameters, selectivity, and cellular activity metrics vary by study and should be confirmed with your own controls and authentic reference data.

General considerations for using bioactive ligands in biology:

• Validate identity/purity and confirm potency in your assay system; activity can be sensitive to cell line, species, and assay format.
• Assess off-target risks by running counterscreens against related pathway components and common anti-targets (e.g., CYPs, transporters) as relevant to your study.
• Consider time-dependence and reversible vs. irreversible engagement; perform washout and dilution series to confirm mode of action.
• Document vehicle effects and final solvent concentrations; include appropriate negative/positive controls.

Buffer Applications

Veliflapon is not a buffering reagent. It is typically used as a bioactive test article prepared in organic stock and diluted into biological buffers.

Practical buffer-related guidance (general):

• Stock preparation: Dissolve in anhydrous DMSO to 10–50 mM. Vortex and, if needed, gently warm (≤40 °C) briefly; avoid prolonged heating.
• Dilution: Add stock to assay buffer (e.g., HEPES, PBS, Tris) to achieve final DMSO ≤1–2% v/v. Mix thoroughly to prevent local supersaturation.
• Precipitation control: If haze forms, consider adding 0.01–0.05% nonionic surfactant (e.g., Tween-20) if compatible, or increase buffer ionic strength modestly. Filter through 0.22 µm if assay allows.
• Adsorption: Hydrophobic ligands can adsorb to plastics; use low-binding tubes/plates and pre-wet tips with vehicle.

Always validate buffer composition for your specific assay endpoint and target class.

Green Alternatives

As a bioactive small molecule, veliflapon is not a solvent or bulk reagent; however, greener choices can be made in its handling and assay setup.

Greener handling choices (general):

• Solvent minimization: Use the highest practical stock concentration in DMSO to reduce total solvent volume in assays.
• Alternative vehicles: Where compatible, consider aqueous solubilization aids (e.g., HP-β-cyclodextrin, 5–10% PEG-400, or minimal ethanol) to reduce DMSO usage.
• Micro-scale operations: Utilize low-dead-volume plates, acoustic dispensing, or pin tools to limit waste.

Comparison of vehicles (general considerations):

• DMSO: Excellent solubilizer; broadly compatible up to ~1–2% v/v in many assays; derived from byproduct streams but requires care in waste handling.
• PEG-400: Low volatility and good safety profile; higher viscosity can complicate dispensing; may affect certain assay readouts.
• HP-β-cyclodextrin: Enhances solubility of hydrophobic ligands via inclusion complexes; compatibility must be validated per assay.

Waste and EHS:

• Consolidate DMSO/organic wastes; avoid aqueous discharge. Choose smallest practical experiment scale to reduce environmental footprint.

Pharmaceutical Uses

No pharmacopeial status or excipient role is provided for this item. This product is supplied strictly for research use only and is not intended for human or veterinary use.

Research/formulation context (general):

• As a bioactive small molecule, veliflapon may be used as a research probe during preclinical studies to interrogate biochemical pathways. Any formulation experiments (e.g., solubility enhancement using cyclodextrins, lipid-based systems, or co-solvents) should remain within laboratory research and method-development contexts.
• If conducting preformulation work, evaluate chemical stability across pH 2–8, oxidative stress (H2O2 challenge), and light exposure; generate forced-degradation profiles to support analytical method specificity (HPLC/UPLC with PDA and MS detection).

No therapeutic claims are made or implied. All use is for laboratory research only.

Physical Properties

Item-specific physico-chemical specifications are not provided in this listing.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point (BP): Not applicable/rarely reported for complex drug-like solids; not specified for this item.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• logP/logD, pKa, refractive index: Not specified for this item; refer to CoA/Spec Sheet.

General handling notes for drug-like small molecules (literature/practice):

• Many screening ligands are hydrophobic and are typically prepared as concentrated DMSO stocks (e.g., 10–50 mM) and then diluted into aqueous assay buffers with final DMSO ≤1–2% v/v to maintain solubility and assay compatibility.
• If aqueous solubility is limited, consider co-solvents (MeOH, ethanol) or excipients (0.01–0.1% Tween-20, 2–10% PEG-400) after verifying assay tolerance.

Always defer to the lot-specific CoA/SDS for authoritative physical data and recommended use conditions.

Quality and Grades

• Grade/Purity: Moligand™ (product data)

What Moligand™ generally implies:

• Intended for screening, binding, or probe development workflows in medicinal chemistry or chemical biology. Lots are typically suitable for in vitro assays and biophysical measurements, not for human/animal use.
• Emphasis on identity confirmation and practical purity appropriate for research screening (often supported by analytical data such as LC/MS or HPLC purity on the CoA).

Important clarifications specific to this listing:

• Exact purity percentage, residual solvents, water content, metals, or stabilizers: Not specified for this item; refer to CoA/Spec Sheet.
• UV cutoff and chromatographic background impurities: Not specified for this item; refer to CoA/Spec Sheet.

Recommendations for users:

• Request or consult the lot-specific CoA to confirm assay-suitable purity (e.g., HPLC chromatogram, MS, NMR snapshot) prior to critical screening runs.
• If using in cell-based assays, consider an extra polish (e.g., preparative HPLC repurification) when absolute compound cleanliness is required; document any repurification in your ELN for reproducibility.
• If the compound is chiral and supplied as a single enantiomer or racemate, this will be indicated on the CoA—verify before SAR interpretation.

Reaction and Applications

This product is supplied as a research ligand for screening and target engagement studies rather than as a synthetic reagent. No manufacturer reaction-use claims are provided.

Research/application contexts (general guidance):

• Chemical biology: Use as a test article in biochemical assays (enzyme/cofactor-dependent pathways), biophysical binding assays (SPR, ITC, DSF), or cell-based reporter assays to assess target engagement. Optimize DMSO stock handling and verify solubility on dilution.
• ADME profiling: Suitable for in vitro assays such as microsomal stability, plasma protein binding, and permeability (e.g., PAMPA, Caco-2) to support probe characterization.
• Orthogonal confirmation: Pair biochemical IC50/EC50 measurements with thermal shift or target occupancy assays to mitigate assay artifacts.

Practical tips:

• Verify identity and purity via LC–MS prior to high-value experiments; confirm absence of reactive impurities that could confound readouts.
• Perform serial dilution in DMSO to minimize precipitation; pre-equilibrate solutions to room temperature before pipetting to avoid DMSO viscosity errors.
• Include vehicle controls matched for solvent content; run counter-screens to assess aggregation or redox interference (e.g., detergent sensitivity tests, Amplex Red for ROS).

Reaction Conditions

No manufacturer reaction-use guidance is provided, and veliflapon is not typically used as a reagent in chemical synthesis.

General lab guidance for solution handling of bioactive ligands:

• Stock solutions: 10–50 mM in dry DMSO; prepare under inert atmosphere if the compound is air/moisture sensitive (verify on CoA).
• Light/oxidation: If literature or preliminary tests indicate photolability or oxidative liability, protect from light (amber vials) and include antioxidants only if proven compatible with your assay.
• Filtration: Use 0.22 µm PTFE filters for DMSO or mixed solvents if particulate matter is observed.

Any reaction parameters (temperature, catalysts, yields) are not applicable to this product’s intended use and are therefore not provided.

Safety and Handling

Hazard classification data are not provided in this listing for veliflapon.

• GHS Classification: Not specified for this item; refer to SDS.
• Signal Word / H-Statements / Pictograms: Not specified for this item; refer to SDS.

General laboratory safety guidance (good practice):

• Handle in a chemical fume hood; avoid inhalation of dust or aerosols.
• PPE: lab coat, nitrile gloves, safety glasses. Upgrade to chemically resistant gloves if using strong solvents.
• Avoid skin/eye contact; wash thoroughly after handling. Prevent environmental release.
• Storage incompatibilities: Keep away from strong oxidizers and strong acids/bases unless compatibility is known. Protect from moisture if the solid is hygroscopic (verify on CoA).
• First aid (overview; defer to SDS): If inhaled—fresh air; if on skin—wash with soap/water; if in eyes—rinse cautiously with water for several minutes; if ingested—rinse mouth. Seek medical attention for persistent symptoms.

Spill/cleanup:

• Small spills: absorb with inert material (e.g., silica, vermiculite), collect in labeled container for disposal.
• Waste: Dispose according to institutional and local regulations; treat as organic laboratory chemical waste.

Note on bioactivity risk: Although for research use only, bioactive ligands can have potent biological effects; minimize exposure and follow SDS guidance.

Solvent Selection

No item-specific solubility data are provided. The following guidance reflects common practice for drug-like small molecules in screening:

• Primary stock solvent: DMSO is typically preferred due to broad solvating power and assay compatibility. Prepare concentrated stocks (e.g., 10–50 mM) and store as frozen aliquots to avoid freeze–thaw cycles.
• Co-solvents: Ethanol or methanol can assist dissolution for initial stock preparation; filter if particulates remain. Avoid high alcohol percentages in biological assays.
• Aqueous buffers: On dilution, maintain final DMSO ≤1–2% v/v to minimize effects on enzymes and cells. Include 0.01–0.05% nonionic surfactant (e.g., Tween-20) if precipitation is observed and is compatible with the assay.
• pH effects: If the compound bears ionizable groups (verify on CoA or literature), adjust buffer pH to favor the desired ionization state to improve solubility or permeability.

Comparison (general):

• DMSO: strongest solvating power; freezer-stable; may affect some targets at >1–2%.
• DMF/NMP: strong solvents but less favored in bioassays due to toxicity and protein denaturation risk.
• PEG-400 or HP-β-cyclodextrin: useful vehicles for low-solubility ligands in ex vivo/biophysical work; check assay tolerance first.

Storage and Reconstitution

• Storage Conditions: Store at -80 °C (product data). Minimize freeze–thaw cycles by aliquoting upon first thaw.
• Shipping: Shipped on dry ice packs + cold packs (product data).
• Container: Keep tightly closed in the original container. If hygroscopic or air-sensitive (verify on CoA), handle under dry inert gas and re-seal with desiccant.

Reconstitution (general guidance for small molecules):

• Solvent: Use anhydrous DMSO for primary stocks unless CoA indicates otherwise. Target 10–50 mM concentration for flexibility in assay dilutions.
• Procedure: Allow vial to equilibrate to room temperature before opening to prevent moisture condensation. Add calculated solvent volume, vortex until fully dissolved, and, if needed, briefly sonicate. Do not overheat.
• Aliquoting: Dispense single-use aliquots into low-binding microtubes; purge headspace with inert gas if stability data suggest air sensitivity. Store aliquots at -80 °C.
• Stability: Item-specific stability, solution shelf life, and thaw limits are not specified for this item; refer to CoA/Spec Sheet. As a conservative practice, discard DMSO stocks after multiple freeze–thaw cycles or >6–12 months at -80 °C unless stability is verified.

For research use only.

Structure and Identity

Veliflapon is listed in our small-molecule library catalog as a Moligand-grade research ligand. Item-specific structural identifiers are limited in this listing.

• SKU: V1496908
• Product Name: Veliflapon
• CAS: 128253-31-6 (product data)
• PubChem CID: 123723 (product data)
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general description):

• Specific functional groups, ring systems, and stereochemistry are not provided in this listing. Consult the Certificate of Analysis (CoA) or SDS for definitive structural identifiers supplied with your lot.

2D structure (verbal description):

• Not specified for this item; refer to CoA/Spec Sheet. If you require structural confirmation prior to use in screening, request spectral data (1H/13C NMR, HRMS) from our technical support or verify against an authenticated reference standard.

Synthetic Utility

Veliflapon is supplied as a finished bioactive ligand and is not typically employed as a synthetic building block.

Notes for synthetic chemists (general):

• If derivatization or probe development is desired (e.g., biotinylation, photoaffinity tagging, fluorophore coupling), first confirm available functional handles (amines, phenols, carboxylates) from authenticated structural data (CoA or literature). Protecting-group strategies and linker installation should preserve the pharmacophore.
• For SAR exploration, establish robust analytics (LC–MS, 1H/13C NMR, HRMS) and purity criteria (>95% by HPLC commonly targeted for bioassays). Consider chiral separation if stereocenters are present.

In summary, the compound’s principal value is as a research ligand for biological interrogation rather than as a reagent in routine synthetic transformations.

Target Specificity

No target specificity data are provided by the manufacturer for this item.

Notes:

• For planning purposes, consult primary literature and databases for veliflapon to understand proposed targets, affinity, and selectivity profiles. Independently confirm target engagement under your assay conditions.
• If you require validated target annotations for this specific lot, contact technical support to inquire about available characterization data or references associated with this product.

Domande frequenti

What is Moligand??

Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 128253-31-6, the molecular formula is C23H23NO3, and the molecular weight is 361.43 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.